Development of proprietary medicines
We look for new medicines in oncology, neuropsychiatry, diabetology and virology
The development of innovative drugs at Adamed is focused on four therapeutic areas: diabetology, oncology, neuropsychiatry and virology. We have the capacity to vigorously execute highly complex projects, such as the development of new molecules, thanks to our multidisciplinary team of experts working in modern laboratories with advanced technological facilities.
Our laboratories enable agile application of technologies which are needed to select and test drug candidates and transfer them to the clinical development stage. We have the know-how to:
- produce small-molecule compounds using chemical synthesis, as well as biological molecules by employing chemical and biotechnological methods;
- analyze the same by chemical, biochemical and biophysical methods;
- study the functionality and efficiency of these molecules by cell or tissue biology methods;
- determine the potential of these molecules to progress to further stages of development by establishing their safety profile in toxicological studies, as well as pharmacokinetic and pharmacodynamic characteristics in in vivo methods.
In our research projects we also use advanced mathematical tools both for data analysis and for in silico modelling during the design phase and when optimizing the molecules which exhibit a therapeutic potential.
Currently, we are implementing projects focusing on six research programmes through which we have selected three molecules which are drug candidates at the stage of transfer to clinical trials. The first one is a licenced-out small molecule developed in indication mental disorders. The second one is a selective MDM2 and p53 protein inhibitor which exhibits cancer-fighting activity in sarcomas, lymphomas, and leukemias. The third molecule is a recombinant fusion protein with pro-apoptotic and anti-angiogenic activity. It is a drug candidate for solid tumors of the gastrointestinal tract.
In the other three research programmes we are in the process of selecting and optimizing molecules. In the first programme, these are anti-cancer molecules and in the other programme, molecules which are intended to be used for treatment of civilization diseases, such as type 2 diabetes and obesity, in the third, fast acting molecules in treatment of depression.
Pipeline
Oncology
Neuropsychiatry
Diabetology
Infectious diseases
Project is co-financed by Medical Research Agency, program: Development of targeted and personalized medicine based on targeted cell therapies and protein products Project value: 35,3B PLN.
The value of the project is PLN 34 749 466.78, of which PLN 18 170 000 are funds from the National Center for Research and Development granted under the Fast Track Program for Mazovia for the project "Clinical development of an innovative anti-cancer compound based on p53 protein activation mechanism”, " "MAZOWSZE / 0012/19-00".
The necessity of finding new oncological therapies and the development of drug resistance in some types of cancer drive the search for new anticancer therapies. As part of this search Adamed initiated 6 early discovery projects in the field of oncology, the most promising of which will be selected for full preclinical development.
The value of the project is over 30 million PLN, which includes more than 19 million PLN of funds from the National Centre for Research and Development granted under the Smart Growth Operational Programme.
The value of the project is over 87 million PLN , of which almost 60 million are funds from the state budget. The project is co-financed by ABM.